GIOVANNA POCE

Si avvisano gli studenti che le lezioni di Analisi dei medicinali I (M-Z) inizieranno il 2/03/2022 alle 15.00 in aula A, CU019 e proseguiranno secondo il seguente calendario

Si rammenta che la frequenza è obbligatoria.

Si avvisano gli studenti che le lezioni di Pharmaceutical chemistry inizieranno il 8/03/2022 alle 16.00 in aula  Psicologia I, CU026 e proseguiranno secondo il seguente calendario

EDUCATION/TRAINING
03/2008: Ph.D. in Medicinal Chemistry. Department of Pharmaceutical Chemistry and
Technology, Sapienza University of Rome, Rome, Italy.
03/2004: Master’s Degree in Pharmaceutical Chemistry and Technology, Department of
Pharmaceutical Chemistry and Technology, Sapienza University of Rome, Rome, Italy.
POSITIONS
11/2024 – to present: coordinator of the PhD course in MOLECULAR DESIGN AND
CHARACTERIZATION FOR THE PROMOTION OF HEALTH AND WELL-BEING: FROM DRUG TO
FOOD
02/2022 - to present: Associate Professor of Medicinal Chemistry, Department of
Pharmaceutical Chemistry and Technology, Sapienza University of Rome, Rome, Italy.
10/2014 - 01/2022: Assistant Professor of Medicinal Chemistry, Department of
Pharmaceutical Chemistry and Technology, Sapienza University of Rome, Rome, Italy.
03/08/2016 - 30/08/2016: Visiting Academic, School of Biomedical Sciences, University of
Cape Town, Cape Town, South Africa.
09/2012 – 09/2014: Research Associate, Department of Pharmaceutical Chemistry and
Technology, Sapienza University of Rome, Rome, Italy.
10/2010 - 08/2012: Visiting Scientist, Department of Immunology and Infectious Diseases,
Harvard School of Public Health, Boston, United States, Group of Professor Eric J. Rubin
04/2008 - 09/2010: Post-doc, Department of Pharmaceutical Chemistry and Technology,
Sapienza University of Rome, Rome, Italy, Group of Professor Mariangela Biava
04/2009 - 10/2009: Academic Visitor, Department of Chemistry, University of Oxford, Oxford,
United Kingdom, Group of Professor Steve G. Davies
04/2008 – 03/2009: Post-doc, Department of Pharmaceutical Chemistry and Technology,
Sapienza University of Rome, Rome, Italy. Group of Professor Mariangela Biava
OTHER EXPERIENCES AND PROFESSIONAL ACHIEVEMENTS
2023-present: Appointed Full Professor of Medicinal Chemistry (Abilitazione Scientifica
Nazionale Professore I Fascia, SSD: CHIM08)
2023-present: Associate editor, Frontiers in Chemistry
2022-present: Section editor, Anti-Cancer Agents in Medicinal Chemistry
2022-present: Section editor, Mini Reviews in Medicinal Chemistry
2020-present: Board member of the PhD course in Molecular design and characterization for
the promotion of health and well-being: from drug to food, Sapienza University of Rome
TEACHING ACTIVITIES
2020/12/12: Member of the evaluation committee for the final defense of the PhD School in
Pharmaceutical Sciences, XXXIII Cycle. Sapienza University of Rome, Rome, Italy.
2021/10/01 To present: Pharmaceutical Chemistry (6 CFU), Faculty of Pharmacy and
Medicine, Degree in Bioinformatics, Sapienza University of Rome, Rome, Italy.
03/2015-present: Drug Analysis I (10CFU), Faculty of Pharmacy and Medicine, Master’s
Degree in Pharmacy, Sapienza University of Rome, Rome, Italy
BIBLIOMETRIC INDICATORS
Type Scopus
Total number of publications (Scopus) 62
H-index 26
Total citations 2077
Book chapters 2
ORAL PRESENTATIONS/SEMINARS AS INVITED SPEAKER
Simple chemistries as enabling tool for advancing antimicrobial research. 2nd Drug Discovery
and Screening Symposium, from Bench to Drug, Institut Pasteur Paris, 7th December 2023,
Paris, France.
Simple Chemistries as Enabling Tool for Advancing TB and Cancer Research. School of
Biomedical Sciences, University of Cape Town, Cape Town, South Africa, 24th August 2016.
(Seminar)
Towards Tuberculosis Treatment with Novel MmpL3 Inhibitors. Dipartimento Dipartimento di
Scienze Farmaceutiche, Università degli Studi di Perugia, 18th March 2014. (Seminar)
BM212-Derived MmpL3 Inhibitors Enabling New Possibilities for the Treatment of
TB.Tuberculosis Drug Development, Gordon Research Conference, Barga (LU), 21-26 July
2013. (Keynote)
Hit-to-Lead Development for a New Class of Anti-Mycobacterial Agents. Tres Cantos Open
LabFoundation, Tres Cantos, 10 June 2013. (Seminar)
1,5-Diphenyl Pyrrolesas New Antimycobacterial Agents. Hit-to-lead Development and Target
Validation. COST Action MeetingCM0801, Siena, 29-31 May 2012. (Oral presentation)
MmpL3 Inhibitors Enabling New Possibilities for TB Treatment. XXII National Meeting on
Medicinal Chemistry, Rome, 10-13 September 2013. (Oral presentation)
Identification of a New Chemical Series of Potent Antimycobacterial Compounds. XX
National Meeting on Medicinal Chemistry, Abano Terme, 12-16 September 2010. (Oral
presentation)
New Pyrrole Derivatives of BM212: a New Class of Antimycobacterial Agents. Design,
Synthesis, Biological Evaluation and Study of Their Mode of Action. NPCFIII, Pisa, 13-14
February 2009. (Oral presentation)
SESSION CHAIRMAN
Novel Frontiers in Nanocarriers Preparation and Characterization, Department of
Pharmaceutical Chemistry and Technology, Sapienza University of Rome, Rome, Italy, 7th
June 2022. 2022https://characterizationwo.wixsite.com/novelnanocarriers
Alternative Approaches to Target ID and Drug Discovery. Tuberculosis Drug Development,
Gordon-Kenan, Research Seminar, Barga (LU), Italy, 20-21 July 2013.
Grants
11/12/2020 – to present: (PI) “Nuovi derivati pirazolici come potenziali agenti antitubercolari”. (Bando dell’Università
di Roma “La Sapienza”. Progetti di Ricerca di Università 2020, n. protocollo
RM120172A80094C4). euro 12000,00
11/12/2019 – 31/10/2020: (PI) “Nuovi derivati tri-antranilati come potenziali agenti antitubercolari”. (Bando
dell’Università di Roma “La Sapienza”. Progetti di Ricerca di Università 2019, n. protocollo
RM11916B883B6B99). euro
37287,00
2017- Finanziamento delle attività base di ricerca, di cui alla legge 11 dicembre 2016 n 232.
Finanziamento ottenuto:
euro 3000,00
2012 – 2014: Project leader “Hit-to-lead development for a new class of antimycobacterial
agents.” Tres Cantos Open
Lab Foundation (GSK, Madrid). euro 134000,00
MAIN RESEARCH INTERESTS
2020-to present: Design, synthesis and characterization of small molecules active as malaria
transmission-blocking agents. Financing Institution: Grand Challenges Africa AESA. In
collaboration with Prof Lyn-Marie Birkholtz and Prof F.
Catteruccia. Role: investigator
2019- to present: Design, synthesis and characterization of small molecules active against
enteroviruses.
In collaboration with Prof V. Mariomaky. Role: PI
2012-to present: Design, synthesis and characterization of small molecules active against M.
tuberculosis hitting
novel targets: MmpL3, iron chelation, tryptophan biosynthetic pathway. Hit-to-Lead
development. DMPK studies, in
vivo efficacy studies. Target identification studies. Financing Institution: Tres Cantos Open
Lab Foundation (GSK,
Madrid); TB Global Alliance. In collaboration with Prof E. J. Rubin and Prof. Kelly Chibale.
Role: PI
COLLABORATIONS
Prof K. Chibale, H3D, Cape Town, SA
Prof E. J. Rubin, Dep Immunol Infect Dis, Harvard TH Chan School of Public Health, Boston,
US
Prof F. Catteruccia, Dep Immunol Infect Dis, Harvard TH Chan School of Public Health,
Boston, US
Prof A. De Logu, Dip Scienze della Vita e dell’Ambiente, Università degli Studi di Cagliari,
Cagliari, Italy
Prof L.M. Birkholtz, Dep of Biochemistry, University of Pretoria, Pretoria, SA
Prof V. Marjomäki, Dep of Biological and Environmental Science, University of Jyväskylä,
Jyväskylä, Finland
Prof M. Mhlanga, Dep of Molecular Biology, Radboud University, Nijmegen, The Netherlands
Dr F. Agou, Institut Pasteur, Paris, France